Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Terapia Ranbaxy, a subsidiary of Ranbaxy Laboratories, will launch Daiichi Sankyo Company's Sevikar, an antihypertensive drug, in Romania.
Subscribe to our email newsletter
The Sevikar, a fixed dose combination of olmesartan medoxomil and amlodipine besylate tablets, is likely to be included on the national lists of compensated drugs.
The combination will provide safe blood pressure decline effect through the complementary actions of its two ingredients.
Ranbaxy CEO and MD Arun Sawhney said, "We are pleased to introduce the first combination of olmesartan + amlodipine for the treatment of hypertension, which is a major public health problem."
The drug will be offered in 5/20mg (amlodipine besylate 5mg, olmesartan medoxomil 20mg), 5/40mg (amlodipine besylate 5mg, olmesartan medoxomil 40mg) and 10/40 mg (amlodipine besylate 10mg, olmesartan medoxomil 40mg) strenghts.
The once-daily, single pill fixed dose combination of the angiotensin receptor blocker olmesartan medoxomil was originally discovered by Daiichi Sankyo.